F17.299 Insurance Policy Changes

ICD-10 F17.299 is officially defined as "Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders." code F17.299 is referenced in 5 tracked payer policy changes from Florida Blue and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code F17.299 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Florida Blue · Effective Jun 1, 2026High impact
Coding Newsletter - Asthma
This is a comprehensive coding newsletter update on asthma diagnosis and documentation requirements effective June 2026. It emphasizes the critical distinction between asthma severity (mild/moderate/severe) and current control status, requiring providers to document both to ensure accurate ICD-10-CM coding. Billing teams must enforce complete documentation including severity, persistence, exacerbation status, and status asthmaticus to support proper code assignment (J45.2-J45.52 series) and capture associated conditions like eosinophilic asthma (J82.83).
Aetna · Identified Oct 7, 2026Medium impact
Brain Natriuretic Peptide Testing (CPB 0618, reviewed 2026-09-29)
Aetna considers measurement of plasma brain natriuretic peptide (BNP) medically necessary to differentiate dyspnea due to heart failure from pulmonary disease, to determine prognosis or severity in chronic heart failure, to screen for heart failure annually in adults with diabetes mellitus, to measure upon hospital admission and before discharge in acutely decompensated heart failure, for preoperative cardiac risk assessment before elevated-risk noncardiac surgery in members with known cardiovascular disease, age 65 or older, or age 45 or older with cardiovascular symptoms, and as an adjunct test for risk stratification of Stage C aortic stenosis. Serial BNP and NT-proBNP measurements and the other uses listed in the policy, such as diagnosing Kawasaki disease, are considered experimental, investigational, or unproven. CPT 83880 is covered when the selection criteria are met, except as a cardiovascular biomarker in healthy normal subjects and for identifying stress-induced myocardial ischemia.
Aetna · Identified Aug 19, 2026Medium impact
Lung Cancer Screening (CPB 0380, reviewed 2026-05-28)
Aetna covers annual low-dose CT (LDCT) lung cancer screening, CPT 71271, for current or former smokers ages 50 to 80 with a 20 pack-year or more smoking history, and former smokers must have quit within the past 15 years. Annual LDCT is also covered for surveillance of non-small cell lung cancer, starting 2 years after definitive treatment, using CPT 71250. Artificial intelligence-based imaging, computer-aided detection for chest radiographs, PET for lung cancer screening, and LDCT screening for other indications such as asbestos-exposed individuals are considered experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)
Aetna considers intensive cardiac rehabilitation programs (the Benson-Henry Institute Cardiac Wellness Program, the Ornish cardiac treatment program and the Pritikin Program) medically necessary as an alternative to traditional Phase II cardiac rehabilitation for members who meet the cardiac rehabilitation criteria, limited to 72 one-hour sessions, up to 6 per day, over a period of up to 18 weeks. Virtual delivery by real-time audio and video (excluding audio-only) is considered medically necessary when the telehealth program and member criteria are met, but hospital outpatient departments are not eligible for virtual telehealth services. Intensive cardiac rehabilitation is considered experimental, investigational or unproven for diabetes, hyperlipidemia, prostate cancer, metabolic syndrome and all other indications where effectiveness has not been established.
Aetna · Identified Aug 12, 2026Medium impact
Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)
Aetna considers automated ambulatory blood pressure monitoring medically necessary when a member meets one of the listed criteria: at least two elevated office readings taken on separate days to identify 'white coat' hypertension; episodic hypertension with symptoms suggesting an adrenal tumor and repeatedly normal office readings; hypotensive symptoms or syncope thought related to antihypertensive medications; syncope evaluated with a 24-hour Holter monitor; nocturnal angina; resistant hypertension before an invasive investigation for secondary causes; or autosomal dominant polycystic kidney disease in children and young adults 30 years of age or younger. Monitoring for less than 24 hours or more than 3 days is not considered medically necessary, and repeat testing is not generally necessary more often than every 6 months. Aetna considers the use experimental, investigational, or unproven for heart failure, for pregnant women who do not meet the criteria, for diagnosing malignant hypertension, for members with an irregular cardiac rhythm such as atrial fibrillation, for routine monitoring to establish a hypertension diagnosis or evaluate treatment response, and for routine use before continuous positive airway pressure (CPAP) therapy.

Watch F17.299

Get one email when a payer policy names F17.299, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code F17.299?

There are 5 tracked policy changes affecting code F17.299, including updates from Florida Blue, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code F17.299?

Payers that have issued tracked updates for code F17.299 include: Florida Blue, Aetna.

How do I get notified when code F17.299 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code F17.299. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code F17.299?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Coding Newsletter - Asthma

Brain Natriuretic Peptide Testing (CPB 0618, reviewed 2026-09-29)

Lung Cancer Screening (CPB 0380, reviewed 2026-05-28)

Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)

Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)

What insurance policy changes affect code F17.299?

Which payers have updated policy for code F17.299?

How do I get notified when code F17.299 policy changes?

Why do payers change policies for code F17.299?